Quantcast
Last updated on April 18, 2014 at 14:37 EDT

Latest Michael Baum Stories

2013-11-11 08:32:06

Exo Labs, Inc. announces reduced price and free shipping to help educators adopt new technology SEATTLE, Nov. 11, 2013 /PRNewswire-iReach/ -- U.S. schools continue to grapple with the growing cost and complexity of educational technology solutions for the classroom. Over the past six months Exo Labs has worked hand-in-hand with educators to identify better ways to put the right technology into the hands of students. According to Exo Labs, Inc. Founder and CEO Michael Baum, "limited...

2013-01-25 09:32:57

Harms from breast cancer screening outweigh benefits if death caused by treatment is included Michael Baum, Professor emeritus of surgery at University College London says that, while deaths from breast cancer may be avoided, any benefit will be more than outweighed by deaths due to the long term adverse effects of treatment. He estimates that, for every 10, 000 women invited for screening, three to four breast cancer deaths are avoided at the cost of 2.72 to 9.25 deaths from the long...

2011-09-26 12:23:38

Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer. Professor Richard Gelber told delegates at the 2011 European Multidisciplinary Cancer Congress, in Stockholm today (Monday 26 September) that a 12-year update of results from...

2011-05-10 07:00:00

LAS VEGAS, May 10, 2011 /PRNewswire/ -- Interop Booth# 627 -- Mu Dynamics, Inc. (www.mudynamics.com), the leader in validating and testing application-aware networks, today announced Michael Baum, the founding CEO of Splunk has joined its board of directors. Michael is a well-known and respected technology innovator and entrepreneur who has gained a reputation for building great companies. "Having Michael join our board is a strong vote of confidence for the innovative steps Mu is...

2006-08-02 18:26:18

By Anthony J. Brown, MD NEW YORK (Reuters Health) - As add-on therapy for early-stage breast cancer, the drug anastrozole, known by the brand name Arimidex, is less likely than tamoxifen to cause adverse effects, including serious events and those leading to treatment discontinuation, new research suggests. In 2005, the results of the "Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial were published and showed a benefit for Arimidex over tamoxifen in terms of disease-free...

2006-03-16 14:33:24

By Nick Smith and Arjen Peters LONDON (Agence de Presse Medicale) - The medical profession is fearful for the future of clinical research and drug development following the clinical trial disaster that has left six men in intensive care, one of the Britain's leading cancer specialists said on Thursday. "The profession is in a state of shock," said Professor Michael Baum, of University College London. "I have been involved in clinical trials for 30 years, and I have never heard of...